Introduction
Prostate cancer is now established as the commonest malignant tumour in males and is a major public health problem in terms of morbidity, treatment cost and mortality. In the USA, an estimated 184,500 new cases and 39,000 prostate cancer-related deaths were predicted for 1998. 1 Yet, despite the prevalence of prostate cancer, many questions remain unanswered. The bene®ts of screening remain unproven, and there is a lack of consensus amongst urologists, epidemiologists and health economists regarding the bene®ts of screening for prostate cancer. We await eagerly the outcome of the PLCO and EORTC screening trials for prostate cancer to resolve this issue. 2 Opinion remains divided on whether we should perform radical prostatectomy or observe patients with organ-con®ned disease, a question being addressed by the PIVOT trial. 3 If we do treat patients with localized prostate cancer, does surgery, radiotherapy or brachytherapy confer greatest bene®t?
When it comes to establishing a diagnosis of prostate cancer, further controversies arise. Digital rectal examination (DRE) combined with prostate speci®c antigen (PSA) testing and subsequent transrectal ultrasound-guided prostatic biopsies is a widely accepted method for detecting prostate cancer. 4 However, in practice, only 21% of men with a PSA between 4 ± 10 ng/ml and normal DRE have prostate cancer 5 and as a result the majority of men in this group undergo prostate biopsy unnecessarily. Clearly, from the viewpoint of the patient and clinician, this is unsatisfactory. Derivatives of PSA (eg free PSA, complex PSA, PSA density, etc) are the focus of much ongoing research in an attempt to improve the speci®city of PSA as a tumour marker. In addition, the role of routine TRUS-guided sextant biopsy of the prostate has been called into question, prompting many clinicians to modify their biopsy regimen in an attempt to improve diagnostic yield. This review will examine the role of TRUS-guided needle biopsy of the prostate in the diagnosis of prostate cancer, focussing on recent studies and controversies as to what constitutes the optimal biopsy regimen.
Transrectal ultrasound
Initially, it was thought that prostate cancer appeared hyperechoic on TRUS. However, early studies were performed using low-frequency (`4 MHz) transducers with poor resolution. 6 With the advent of high-frequency transducers (7.5 MHz) , it emerged that the commonest appearance for cancer was a hypoechoic area in the peripheral zone of the prostate. 7 However, not all hypoechoic regions represent cancer. Other conditions such as benign prostatic hyperplasia (BPH), cysts, blood vessels, in¯ammatory foci and prostatic intraepithelial neoplasia (PIN) can appear hypoechoic on TRUS. 8, 9 Conversely, not all cancers are hypoechoic, with as many as 32 ± 42% of prostate cancers being reported as isoechoic. 10 ± 12 These lesions may be palpable without being visible on sonography, underlining the importance of performing a DRE prior to inserting the TRUS probe.
Because of its limited sensitivity and speci®city, TRUS is not an appropriate screening tool for prostate cancer. 13 However, TRUS-guided needle biopsy of the prostate has become the method of choice in obtaining a tissue specimen for diagnosis in patients with suspected prostate cancer. Recent improvements in biopsy needles mounted on spring-loaded guns have improved the quality of the tissue core obtained while minimizing patient discomfort. TRUS allows accurate placement of the biopsy needle facilitating biopsy of suspicious hypoechoic lesions as well as palpable abnormalities on DRE. In general, the technique is well tolerated by patients and can be performed with major morbidity of`1% if carried out under appropriate antibiotic cover. 14 The sensitivity and speci®city of TRUS in detecting prostate cancer has been reported as 53.3% and 75%, respectively, 15 while a later report noted that sextant biopsies had an overall sensitivity of 60% with a speci®city of 100%. Sensitivity could be increased to 83% if cancers greater than 2 cm 3 in volume only were considered. 16 In the era of TRUS-guided prostatic biopsies, a number of clinical dilemmas have arisen, including whether to perform random biopsies or directed biopsies of sonographic and/or palpable abnormalities. Other controversies exist regarding the number of biopsies to be performed and from what region of the prostate they should be taken. Sceptics suggest that, by subjecting all men with signi®cantly elevated PSA to TRUS-guided biopsy, we risk detecting clinically insigni®cant tumours. When the patient's PSA continues to rise or a high clinical suspicion of cancer exists, but the prostate biopsies show no de®nite evidence of cancer, a further dilemma exists. The urologist must then balance the potential bene®ts to the patient of a positive repeat biopsy against the risks of possible further negative biopsies and morbidity associated with the procedure.
Lesion-directed vs random sextant biopsies
The widely practiced technique of random systematic sextant prostatic biopsies was pioneered by the Stanford group in 1989. 17 Using this technique, tissue cores are obtained bilaterally in the para-saggital plane, sampling the apex, mid-region and base of the prostate at intervals approximately 1 cm apart. It was shown that this method was more likely to detect cancer when compared with directed biopsies of hypoechoic areas alone. One-hundred and thirty-six men with palpably abnormal prostates underwent random sextant biopsies, while an additional 57 of these had additional directed biopsies aimed at hypoechoic areas not included in the sextant biopsy protocol. Cancer was diagnosed in 83 (61%) patients. Of these, the random sextant biopsy method detected 80 of 83 (96%) tumours while only three (4%) patients had their cancer detected by directed biopsy alone. 17 Subsequently, in a study of 175 patients with clinical evidence of stage B and C disease, TRUS identi®ed 157 (90%) men with prostate cancer. Sextant biopsies were equally effective in diagnosing cancer irrespective of the presence or absence of hypoechoic lesions. 18 In a further study, where sextant biopsies were performed on 100 men with clinically benign prostate glands on DRE, 14 cancers were detected, 12 of which were isoechoic. Of 18 hypoechoic lesions noted, only two revealed cancer on biopsy and, of these, one patient had concomitant cancer detected by random sextant biopsies. 19 In a study of 41 men with suspected prostate cancer, while sextant biopsies alone detected 82% of cancers and lateral peripheral zone biopsies alone detected 70% of cancers, when both techniques were combined, the cancer detection rate increased to 96%. This compared with a cancer detection of 59% if only hypoechoic lesions were targeted for biopsy. The authors concluded that combining both systematic sextant and lateral peripheral zone biopsies would detect the majority of prostate cancers and eliminate the need for lesion-directed biopsies. 20 In contrast, in a large prospective trial from Sweden of more than 500 men with suspected prostate cancer, it was shown that by taking additional targeted biopsies from sonographically abnormal regions outside the location of standard sextant biopsies, the sensitivity increased from 85% to 93%. Here, 15% of cancers would have been undetected by the standard sextant protocol compared with a more extensive biopsy regimen combining systematic and lesion-directed sampling. 21 
Systematic sextant vs extended core biopsies
Given the reported sensitivity of the sextant biopsy technique, it is inevitable that many false-negative prostate biopsies will be performed. Concern exists that the sextant biopsy method does not provide adequate sampling of the prostate gland in all instances, particularly where the prostate is enlarged due to concomitant BPH. The majority of prostate cancers arise in the peripheral zone, 22 which frequently becomes compressed by the expanding transition zone in BPH. As a consequence, it has been suggested that needle placement for systematic sextant biopsies be shifted laterally to improve sampling of the peripheral zone. 23 In a study of 41 men with suspected carcinoma of the prostate, both mid-lobe (para-saggital) sextant biopsies and lateral sextant biopsies were obtained. Cancer was detected by both methods in 46.3% of patients, while in 14.6% the lateral biopsies alone were positive compared with 7.3% of patients where mid-lobe biopsies alone were positive. 20 The authors suggest that laterally placed systematic sextant biopsies could improve the diagnostic yield of needle biopsies in men with suspected carcinoma of the prostate, particularly where there was palpable lateral nodularity or a normal DRE but elevated PSA and in patients undergoing repeat biopsy. Another study of 273 consecutive men referred for TRUS and biopsy because of an elevated serum PSA level, abnormal DRE or both, found that the addition of lateral peripheral zone biopsies increased the sensitivity of cancer detection, identifying 77% of cancers missed by the systematic sextant biopsy protocol alone, and practically eliminating the need for lesion-directed biopsies. 24 A systematic ®ve-region biopsy technique has been proposed where, in addition to random sextant biopsies, two sets of lateral peripheral zone and 3 midline biopsies were obtained. 25 Twelve to 15 cores were taken where the prostate volume was less than 50 cm 3 and up to 18 cores if the prostate was larger than 50 cm 3 . An improvement in diagnostic yield of 35% over the systematic sextant biopsy method alone was noted, with 83% of the additional tumours identi®ed having a Gleason score of six or more. 25 Levine and coworkers noted that cancer detection rates could be increased by 30% by performing two consecutive sets of sextant biopsies at a single of®ce visit. 26 Prostate size was a factor in cancer detection, as 43% of men in whom prostate volume was less than 30 cm 3 had cancer detected compared with 24% of men with prostate volumes exceeding 50 cm 3 .
Increasing the number of biopsies without altering the areas biopsied may not improve the detection rate for cancer, however. A recent study examined the diagnostic value of performing 10 systematic biopsies in 162 consecutive patients with a serum PSA b 4 ng/ml with or without an abnormal DRE. 27 In addition to the standard sextant biopsy regimen, two further para-saggital biopsies were obtained bilaterally, one between the standard apical and mid-gland biopsy sites, the other between the mid-gland and basal biopsy sites. A total of ®ve biopsies were taken from each side of the prostate, all in the same plane and at the same angle. The additional biopsies yielded a mere 3% diagnostic improvement when compared with systematic sextant biopsies alone leading the authors to conclude that without altering the angle of biopsy or the area of the prostate sampled, no signi®cant increase in positive biopsy rate will result. 27 Perhaps the most sensible approach to this issue is that proposed by Presti and coworkers, who performed lateral peripheral zone biopsies of the base (two) and mid-gland (two) in addition to routine sextant biopsies in 483 consecutive men referred for biopsy with an abnormal DRE and/or an elevated serum PSA. 28 Two-hundred and two cancers (42%) were detected, the majority (96%) by the combination of lateral peripheral zone and sextant biopsies. Of the eight`missed' cancers, ®ve were detected by lesion directed biopsies. Three further cancers were found in the transition zone, which was biopsied only if prostate volume exceeded 50 cm 3 . If mid-lobar base biopsies were omitted from the protocol, the resultant eight-biopsy peripheral zone regimen detected 95% of tumours. 28 The systematic sextant biopsy method, widely practiced for a decade now, is inadequate and more extensive biopsy protocols that obtain a minimum of eight tissue cores, particularly from the lateral peripheral zones should be performed.
Should the transition zone be routinely biopsied?
Although the majority of tumours arise in the peripheral zone, up to 24% of prostate cancers originate in the transition zone. 22 These transition zone cancers are thought to have a favourable prognosis, being of low Gleason grade, infrequently associated with PIN 29 and are often discovered incidentally during TURP (stage T1a or T1b). However, some authors have recommended routine transition zone biopsies for all men who present with a raised PSA in conjunction with a normal DRE. 30 This approach may not be necessary in all patients, particularly at the time of initial biopsy.
In one series examining the indications for transition zone biopsy in men with suspected prostate cancer, 26.4% of patients had cancer con®ned exclusively to the transition zone. 31 Other studies have reported rates signi®-cantly lower than this. Of 847 men who underwent TRUS-guided systematic sextant and transition zone biopsies, only eight (2.9%) patients (4.1% if only stage T1c considered) had solitary transition zone tumours. 32 Terris noted that patients undergoing routine transition zone biopsies, in addition to sextant biopsies, had positive biopsies involving the transition zone alone in 1.8% of cases. 33 In a similar study, isolated transition zone cancer was found in only 2.6% of men biopsied. 34 The Johns Hopkins group performed repeat sextant and transition zone biopsies in the pathology laboratory on 193 radical prostatectomy specimens removed from men with clinical T1c tumours. They found that the transition zone biopsy by itself was positive in only 2.1% of cases, concluding that routine transition zone biopsies are not justi®ed in light of such low detection rates. 35 Black men undergoing radical prostatectomy were noted to be twice as likely as White patients to have tumours con®ned to the transition zone. 36 However, other investigators have shown that when variables such as age, PSA and PSA density were controlled for, no signi®cant racial differences in cancer detection rates in routine transition zone biopsies were noted between Black (3%) and White (0%) males. 37 It is likely that a false-negative prostate biopsy results more commonly from failure to adequately sample the peripheral zone than from missing occult transition zone tumours. Nonetheless, if there is a role for transition zone biopsy, it is where there is a high clinical suspicion of cancer, but the initial set of sextant biopsies has been negative. One such study found that 53% of such patients had exclusive transition zone tumours detected on repeat biopsy, where prior biopsies were negative, 31 although this ®gure was only 10% in another reported series. 38 Another group noted that only 4.3% of patients in their study had transition zone biopsies alone that were positive for cancer, although in three patients with both positive peripheral and transition zone biopsies, the tumours were upgraded based on the transition zone specimen. Interestingly, no patient with a sonographic abnormality noted in the transition zone had cancer on biopsy. 39 Others have also found a low detection rate for targeted biopsies of hypoechoic lesions in the transition zone. 40 If up to 24% of prostate cancers arise in the transition zone, 22 why is the incidence of TRUS-detected transition zone cancer so low? It is possible that the incidence of positive transition zone biopsies in screen detected (asymptomatic) patients is lower than in patients presenting with lower urinary tract symptoms in conjunction with a raised PSA. From our experience, such patients are more commonly seen in the UK and more than 10% of such individuals will have isolated transition zone tumours. 41 The low diagnostic yield of systematic transition zone biopsy at the time of initial biopsy argues strongly against their routine use for detection of early stage prostate cancer. However, performing transition zone biopsies as part of a protocol of repeat systematic biopsies in selected men with prior negative biopsies may sometimes provide important information, additional to that obtained by repeating sextant biopsies alone.
Repeat TRUS-guided prostate biopsy: who needs it?
Frequently, urologists are faced with the dilemma of treating a patient with a high index of suspicion of prostate cancer, but an initial set of negative biopsies. As prostate cancer is often multifocal and the volume of prostate sampled by the standard sextant biopsy technique relatively small, the possibility remains that these individuals may harbour cancer, despite an initial set of biopsies which are negative for cancer. As previously discussed, increasing the number of biopsies and sampling wider areas of the prostate, particularly the lateral peripheral zones, should improve the detection rate of cancer at the time of initial biopsy, thereby reducing the number of men with falsely negative biopsies.
Clear indications for repeating TRUS-guided prostatic needle biopsies include initial biopsies reported as inadequate for diagnosis or suspicious, but not diagnostic for cancer. The presence of high-grade PIN in the initial biopsy is a signi®cant risk factor for cancer on subsequent biopsy 42 and, as such, represents an absolute indication for repeat biopsy. In one reported series 100% of patients with high grade PIN on initial biopsy were subsequently found to have cancer on rebiopsy. 43 The signi®cance of other atypia apart from PIN on initial biopsy in relation to repeat biopsy outcome is not as well de®ned, but most would also consider this to be an indication to perform further sets of biopsies. In a follow-up study of men with atypical initial biopsies, almost 50% of patients rebiopsied had cancer, 4% had high-grade PIN and 9% had an atypical repeat biopsy. 44 But what of men with a normal (benign) initial biopsy? This group represents by far the largest diagnostic group on initial biopsy, comprising between 48 and 69% of patients in reported studies, and yet up to 25% of these individuals will have cancer on repeat biopsy. 43, 45, 46 Fleshner de®ned a subgroup of patients thought to be at lowest risk of cancer (PSA`10, PSA density`0.15, PSA velocity`0.75 ng/ml/y, no PIN, normal DRE, normal TRUS and a negative family history for prostate cancer), but found that 24% of such patients had cancer on repeat biopsy. 47 The Johns Hopkins group warned that, although prior benign biopsies were more common in men with larger glands or with anterior or lateral cancers, the majority ( b 70%) of tumours subsequently diagnosed in these men were considered to be clinically signi®cant. 48 Overall, in men with negative initial biopsies, cancer detection rates of 19 ± 31% have been reported for men undergoing repeat biopsy. 43, 45, 46 A rising PSA velocity may be a useful marker in patients with initial negative biopsies to identify those patients that will subsequently be found to have cancer on repeat biopsy. 46 Although re®ning PSA and its molecular forms, improving our biopsy technique and use of newer technologies such as bioimpedance 49 and arti®cial neural networks 50 may all help reduce the incidence of false negative initial biopsies, at present, clinicians have little option but to rebiopsy all men where a high index of suspicion for carcinoma of the prostate exists, despite an initial set of negative biopsies.
Does TRUS-guided prostate biopsy detect clinically insigni®cant disease?
Autopsy data suggest that as many as one-third of men older than 50 y of age will have histological evidence of prostate cancer. 51 Others have estimated that a 50-y-old male has a 42% lifetime risk of harbouring a histological malignancy, but only a 9.5% lifetime risk of developing clinically detectable prostate cancer 52 and, overall, less than 3% of men will die from the disease. 53 In view of these observations concern has arisen that the current practice of performing needle biopsies of the prostate risks detecting clinically insigni®cant disease and, as a consequence, men with such tumours might needlessly be subjected to radical surgery or radiotherapy and their associated complications.
What constitutes a`clinically insigni®cant' prostate cancer? Microscopically, a clinically detected tumour may have similar histological features to one found incidentally at necroscopy or cystoprostatectomy for bladder cancer. However, these tumours will differ from their clinically detected counterparts in terms of established prognostic features such as volume and grade. Stamey de®ned an insigni®cant tumour as one measuring less than 0.5 cm 3 in volume. 54 This de®nition was later expanded to include any tumour con®ned to the prostate, with a Gleason grade no higher than 3 and a volume of less than 0.5 cm 3 . 55 While there is general agreement in terms of extracapsular extension and Gleason grade (see Table 1 ), others argue that only those tumours with a volume of`0.2 cm 3 should be considered insigni®cant. 56 Several studies have since addressed the issue of whether certain cancers detected by TRUS-guided biopsy (especially stage T1c tumours) are clinically signi®cant.
Terris and associates noted that the overall risk of detecting insigni®cant (`0.5 cm 3 ) cancer on systematic biopsies of the prostate was 4%. This could be further decreased to 1.4% by performing con®rmatory biopsies on all patients where less than 3 mm of cancer was identi®ed in only one of the six cores obtained. Patients with no cancer or only another tiny (`3 mm) focus of cancer on repeat biopsy were managed conservatively and followed with serial DRE and PSA levels every 6 ± 12 months. 57 Ohori found that of 306 clinically detected cancers treated by radical prostatectomy, only 9% were insigni®cant (`0.5 cm 3 , Gleason grade 1 ± 3 only, organ con®ned) while 29% were advanced (extensive extracapsular extension, seminal vesicle invasion or lymph node metastases). In contrast, of 90 incidental cancers found at cystoprostatectomy, 78% were insigni®cant and the remainder were curable, with no tumour being advanced. Of interest, the detection of impalpable cancers by PSA or TRUS decreased the proportion of advanced cancers detected without increasing the detection rate of clinically insigni®cant disease. 55 Epstein studied a series of 157 consecutive men who underwent radical prostatectomy for clinical stage T1c disease and de®ned three pathological variables on needle biopsy that were predictive of clinically signi®cant cancer. 56 These were (i) any Gleason pattern 4 or 5 present in the biopsy; (ii) three or more cores with tumour involvement; (iii) any core with b 50% involvement with tumour. This group of patients did not undergo a standardized regimen of systematic sextant biopsies, however. Sixteen percent of tumours were classi®ed as insigni®cant (`0.2 cm 3 , con®ned to prostate, Gleason score`7), 10% were minimal (0.2 ± 0.5 cm 3 , con®ned to prostate, Gleason score`7), 37% were moderate ( b 0.5 cm 3 , or capsular penetration, Gleason score`7) and 37% were advanced (capsular penetration, Gleason score 7, or positive margins, lymph nodes or seminal vesicles). Using stepwise multiple regression analysis, the best model to predict the presence of a clinically signi®-cant tumour was a PSA density of b 0.1 ng/ml/g or any adverse pathology on needle biopsy (except where the PSA density was 0.1 ± 0.15, with a Gleason grade of`4 present in only one biopsy core). In this way, 93% of moderate or advanced tumours were identi®ed correctly, as were 73% of tumours deemed to be insigni®cant. 56 This group of men was then compared with a later cohort of 336 patients with stage T1c prostate cancer, using the same criteria to de®ne insigni®cant, minimal, moderate and advanced tumours. Two-hundred and forty men (71%) in this group underwent radical prostatectomy, 20 (6%) had radiation therapy and 76 (23%) were managed by watchful waiting. Of the 240 men who underwent radical prostatectomy, tumours were insigni®cant in 40 (17%), minimal in 29 (12%), moderate in 124 (52%) and advanced in 47 (19%) . Overall, an increase in organcon®ned cancers and a decrease in positive margins were noted when compared with the earlier series of 157 patients, probably as a result of widespread PSA testing, but most notably, the percentage of insigni®cant tumours remained unchanged. 58 For tumours detected through PSA-based screening, 16% of cancers detected were subsequently deemed to be clinically insigni®cant. 59 In this instance, an insigni®cant tumour was de®ned as impalpable, microscopically focal (no cut-off volume given) and well differentiated (no Gleason grade 3 or higher present). However, only 3% of men who subsequently underwent surgical staging were found to have clinically insigni®cant tumours by this de®nition. 59 While it is reassuring that only a tiny minority of men in this study underwent unnecessary radical surgery, it is of concern that if those 16% of men thought to have insigni®cant disease by clinical staging were managed expectantly, most would have had a clinically important tumour left untreated. Such tumours may subsequently progress beyond the stage where cure is possible before they are considered clinically signi®-cant. Most clinicians as a result tend to regard all cancers as potentially lethal, given that current methods of clinical staging may fail to provide a suf®ciently accurate estimate of prognosis. 
Complications of TRUS-guided prostate biopsy
In general, TRUS-guided prostate biopsies are well tolerated and can be performed as an out-patient procedure without the need for sedation or narcotic analgesia. The procedure is associated with some discomfort, the degree of which is probably related to site and number of biopsies obtained, although it has been shown that 12 biopsy cores can be safely obtained without any signi®-cant increase in pain scores or morbidity when compared to the sextant method. 60 Others have reported that in®l-tration of 1% lignocaine into the periprostatic neurovascular plexus prior to biopsy has no associated morbidity and can signi®cantly reduce the discomfort patients associate with the procedure. 61 Table 2 shows the reported complications of TRUSguided prostatic biopsies which include haematuria, blood in the stool, haematospermia and pain. 62, 63 In one study incorporating a systematic ®ve-region extended core biopsy protocol, adding far lateral and medially directed biopsies to the standard sextant method, 80% of patients experienced haematuria (self-limiting, not requiring intervention), probably as a result of biopsies in the midline encroaching on or penetrating the urethra. As only two additional tumours were detected by biopsies from the midline of the prostate, the authors suggest that this region can be reasonably eliminated from the extended core biopsy regimen, reducing the incidence of haematuria without compromising cancer detection. 25 Extensive sampling of the prostate may also cause transient prostatic oedema resulting in bladder outlet obstruction and acute urinary retention. In a recent report, 10% of men undergoing extensive repeat biopsies (range, 15 ± 31 biopsies; mean, 22.5 biopsies), where previous sextant biopsies had been negative for cancer, developed urinary retention. All patients subsequently voided spontaneously following temporary catheterization for 72 h. 64 To preserve the reputation of TRUS-guided biopsy as an out-patient technique with a high safety pro®le, clinicians should carefully balance the bene®ts to the patient of a positive histological diagnosis against the risk of complications, especially where large numbers of biopsies are performed.
With appropriate antibiotic prophylaxis, infectious complications are infrequent, but include septicaemia 65 prostatic abscess 66 and Pseudomonas urinary tract infection. 67 Rodriguez and Terris prospectively studied the risks and complications of TRUS-guided prostate needle biopsy in 128 consecutive men with suspected prostate cancer. Systematic sextant biopsies were obtained with an 18 gauge needle mounted on a spring-loaded biopsy gun. All patients received an enema and a combination of metronidazole and cipro¯oxacin an hour prior to biopsy. Only one patient had a major complication necessitating hospital admission (vasovagal episode and seizure), but most patients (63.6%) had at least one minor complication. Persistent haematuria was the commonest complication (47.1%) and bore no relation to number of biopsies performed or recent ingestion of aspirin or nonsteroidal anti-in¯ammatory agents. Only 2.5% of patients experienced infectious complications, all treated on an out-patient basis with no signi®cant sequelae. Cancer was detected in 45.2% of patients and the presence of cancer on biopsy did not place patients at higher risk of complications. 68 Conclusions TRUS-guided systematic biopsies of the prostate are a highly effective means of detecting prostate cancer. In the PSA era, when a signi®cant number of tumours diagnosed are clinically impalpable, the true utility of TRUS is to permit sampling of all relevant areas of the prostate including those that appear ultrasonically normal. 69 By increasing the number of biopsy cores obtained and by sampling more areas of the prostate gland, cancer detection rates are signi®cantly improved and the need for performing lesion-directed biopsies almost eliminated. Routine transition zone biopsies are probably not indicated but may be useful where the patient is undergoing repeat biopsy. If the initial set of biopsies is negative for cancer, and there is a high clinical index of suspicion, all patients in this situation should undergo at least one further set of biopsies, particularly where high-grade PIN has been detected. The risk of detecting clinically insigni®cant cancer ranges from 4 to 16% and many would advocate managing such patients expectantly. Unfortunately, clinical staging has limitations and a number of these patients may actually have signi®cant cancers when surgically staged. TRUS-guided biopsies of the prostate are well tolerated with a low incidence of major complications. However, the incidence of minor complications is high, with haematuria being the most common. TRUS-guided biopsies remain the gold standard in establishing a diagnosis of prostate cancer and, undoubtedly, re®nements in PSA testing and newer technologies will help further improve performance in this regard. 
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